<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00250523</url>
  </required_header>
  <id_info>
    <org_study_id>PRO 0801232</org_study_id>
    <secondary_id>P50GM053789-09</secondary_id>
    <nct_id>NCT00250523</nct_id>
  </id_info>
  <brief_title>Mathematical Modeling of the Acute Inflammatory Response Following Injury</brief_title>
  <official_title>Mathematical Modeling of the Acute Inflammatory Response Following Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of General Medical Sciences (NIGMS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of General Medical Sciences (NIGMS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to gather clinical and biologic information from&#xD;
      severely injured patients to better understand and characterize the host response to injury&#xD;
      and inflammation across several domains. This information may improve outcome prediction,&#xD;
      improve clinical treatment of injured patients, and permit the construction of non-biologic&#xD;
      computerized models of illness that can be utilized to represent the host response in future&#xD;
      research efforts. This study is designed as the calibration of a mathematical model of this&#xD;
      response with predictive capabilities.&#xD;
&#xD;
      The central hypothesis governing this study is that adaptive immune elements are crucial to&#xD;
      determining the outcome of complex inflammatory scenarios. We propose to test these&#xD;
      hypotheses in the following interrelated Specific Aims:&#xD;
&#xD;
      Specific Aim 1: To develop a robust mathematical model describing trauma/hemorrhage-induced&#xD;
      inflammation in humans, its pathologic consequences, and possible therapies.&#xD;
&#xD;
      Specific Aim 2: To translate the mathematical model to humans and create software aimed at&#xD;
      individualized clinical decision-making.&#xD;
&#xD;
      Specific Aim 3: To determine the prevalence of an IL-1 receptor-associated kinase (IRAK-1)&#xD;
      variant haplotype located on the X-chromosome in an injured population, and to characterize&#xD;
      differences in the pro-inflammatory response across gender, relative to the IRAK-1 haplotype.&#xD;
&#xD;
      Specific Aim 4: To determine if increased arginase activity previously observed in isolated&#xD;
      peripheral blood mononuclear cells of trauma patients is a consequence of the presence of&#xD;
      contaminating activated granulocytes or a particular subset of an arginase positive monocyte&#xD;
      subset.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2003</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Multiple Organ Failure</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Trauma</condition>
  <condition>Critical Illness</condition>
  <arm_group>
    <arm_group_label>Traumatic injury</arm_group_label>
    <description>ICU Patients with blunt or penetrating injury</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Healthy volunteers</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      For trauma injury cohort: The maximum blood volume collected over the 28 day period, if all&#xD;
      samples are obtained, is approximately 90 cc. All standard precautions will be undertaken to&#xD;
      assure minimal risk.&#xD;
&#xD;
      Blood samples will be obtained for genetic analysis of inflammatory gene polymorphisms. We&#xD;
      will collect whole blood, serum and white cells.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects to be recruited will consist of trauma patients and healthy volunteers:&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Trauma patient cohort inclusion criteria:&#xD;
&#xD;
          -  Present for treatment of their acute, blunt or penetrating injuries to the University&#xD;
             of Pittsburgh Medical Center within 6 hours of injury&#xD;
&#xD;
          -  Age greater than or equal to 18 years&#xD;
&#xD;
          -  Intact cervical spinal cord&#xD;
&#xD;
          -  Are admitted to the Intensive Care Unit&#xD;
&#xD;
        Trauma patient cohort exclusion criteria:&#xD;
&#xD;
          -  Anticipated survival &lt; 24 hrs&#xD;
&#xD;
          -  Anticipated survival &lt; 28 days due to pre-existing condition&#xD;
&#xD;
          -  Traumatic Brain injury (GCS â‰¤8 after ICU admission) AND brain CT abnormality within 12&#xD;
             hr of injury&#xD;
&#xD;
          -  Inability to obtain consent from the subject or their legally authorized&#xD;
             representative.&#xD;
&#xD;
          -  Pre-existing immunosuppression&#xD;
&#xD;
          -  Transplant recipient&#xD;
&#xD;
          -  Chronic high doses of steroids (&gt;20 mg prednisone equivalents/day)&#xD;
&#xD;
          -  Significant likelihood of high dose steroids (e.g. spinal cord injury)&#xD;
&#xD;
          -  Oncolytic drug(s) therapy within the past 14 days&#xD;
&#xD;
          -  Known HIV positive status and CD4 count &lt; 200 cells/mm3&#xD;
&#xD;
          -  Admission to the ICU primary for substance withdrawal.&#xD;
&#xD;
          -  Inability to obtain 1st blood sample within 24 hours of injury.&#xD;
&#xD;
        Healthy volunteer cohort inclusion:&#xD;
&#xD;
          -  Age greater than or equal to 18 years&#xD;
&#xD;
          -  Weight &gt; 110 pounds&#xD;
&#xD;
          -  no recent illness or infection in the last two weeks&#xD;
&#xD;
          -  no recent hospitalization or trauma in the last month&#xD;
&#xD;
        Healthy volunteer cohort exclusion:&#xD;
&#xD;
          -  wt &lt; 110 lbs&#xD;
&#xD;
          -  infection or illness in the last two weeks&#xD;
&#xD;
          -  Hospitalization or trauma in the last month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason L Sperry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UPMC Department of Surgery/Critical Care Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stacy D Stull, MS</last_name>
    <phone>412-692-4338</phone>
    <email>stullsd@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jason L Sperry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 7, 2005</study_first_submitted>
  <study_first_submitted_qc>November 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2005</study_first_posted>
  <last_update_submitted>March 1, 2021</last_update_submitted>
  <last_update_submitted_qc>March 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of General Medical Sciences (NIGMS)</investigator_affiliation>
    <investigator_full_name>Dr Jason L Sperry</investigator_full_name>
    <investigator_title>Professor of Surgery and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>trauma</keyword>
  <keyword>critical illness</keyword>
  <keyword>injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

